IP Library Granted Patent US 8,669,269
Granted Patent B2
US 8,669,269 · App. 13/132,564 · Granted Mar 11, 2014

Imidazopyridine derivatives which inhibit the secretion of gastric acid

Inventor: Mikael Dahlstrom (Bromarv, FI)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,669,269
App. No.
13/132,564
Granted
Mar 11, 2014
Kind
B2
Abstract

The present invention relates to substituted imidazo[1,2-a]pyridines of formula I where R is —CH 2 COOH or —COOH, which inhibits exogenously or endogenously stimulated gastric acid secretion and can be used in the prevention and treatment of gastric acid related diseases and gastrointestinal inflammatory diseases.

Claims (16)

1. A substituted imidazo[1,2-a]pyridine of formula I or a pharmaceutically acceptable salt thereof

where R is —CH 2 COOH or —COOH.

2. The substituted imidazo[1,2-a]pyridine according to claim 1 , wherein the compound of formula I is 5-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid or a pharmaceutically acceptable salt thereof.

3. The substituted imidazo[1,2-a]pyridine according to claim 1 , wherein the compound of formula I is 4-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}carbonyl)-amino]ethoxy}-4-oxobutanoic acid or a pharmaceutically acceptable salt thereof.

4. The substituted imidazo[1,2-a]pyridine according to claim 1 , form by reacting 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide of formula II

with an anhydride selected from glutaric anhydride and/or succinic anhydride in a solvent at a temperature ranging from 40 to 130° C.

5. The substituted imidazo[1,2-a]pyridine according to claim 4 , wherein the solvent is selected from the group consisting of dimethylformamide, dimethylacetamide, N-methylpyrrolidone, tetrahydrofurane, cyclic ketones and alicyclic ketones.

6. The substituted imidazo[1,2-a]pyridine according to claim 4 , wherein the process is carried out under a pressure ranging from atmospheric pressure to 5×10 2 Kpa.

7. The substituted imidazo[1,2-a]pyridine according to claim 1 wherein the substituted imidazo[1,2-a]pyridine of formula I or a pharmaceutically acceptable salt thereof

where R is —CH 2 COOH or —COOH is in combination with a pharmaceutically acceptable diluent or carrier.

8. A process for preparation of a substituted imidazo[1,2-a]pyridine including the following steps:

a) providing 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide of formula III:

b) reacting step a) with an anhydride selected from glutaric anhydride and/or succinic anhydride in a solvent at a temperature ranging from 40 to 130° C., wherein a final product is a substituted imidazo[1,2-a]pyridine of formula IV or a pharmaceutically acceptable salt thereof

where R is —CH 2 COOH or —COOH.

9. The process according to claim 8 , wherein the solvent is selected from the group consisting of dimethylformamide, dimethylacetamide, N-methylpyrrolidone, tetrahydrofurane, cyclic ketones and alicyclic ketones.

10. The process according to claim 9 , wherein the process is carried out under a pressure ranging from atmospheric pressure to 5×10 2 Kpa.

Assignments (6)
SECURITY INTEREST Recorded Mar 17, 2026
From: CINCLUS PHARMA HOLDING AB (PUBL)
To: CLARET EUROPEAN SPECIALTY LENDING COMPANY IV, S.A R.L.
Reel/Frame 074101/0599 →
CHANGE OF NAME Recorded Dec 16, 2022
From: BEACON PRIVATE EQUITY GROUP AG
To: CINCLUS PHARMA AG
Reel/Frame 063053/0974 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2022
From: DAHLSTROM, MIKAEL; ANDERSSON, KJELL; UNGE, PETER
To: BEACON PRIVATE EQUITY GROUP AG
Reel/Frame 062122/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2022
From: CINCLUS PHARMA AG
To: CINCLUS PHARMA HOLDING AB
Reel/Frame 062122/0973 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2022
From: DAHLSTROM, MIKAEL
To: ANDERSSON, KJELL; UNGE, PETER; DAHLSTROM, MIKAEL
Reel/Frame 062150/0423 →
CHANGE OF NAME Recorded Dec 16, 2022
From: CINCLUS PHARMA HOLDING AB
To: CINCLUS PHARMA HOLDING AB (PUBL)
Reel/Frame 062150/0480 →
Priority Claims (1)
FI 20086158 · Dec 3, 2008 · national
Continuity (1)
Related Publication 20110237619A1 · Sep 29, 2011